Icilin inhibits E2F1-mediated cell cycle regulatory programs in prostate cancer

Biochemical and Biophysical Research Communications

Volumn 441, Issue 4, 2013, Pages 1005-1010

  Lee, Sanghoon ^a   Chun, Jung Nyeo ^b,c   Kim, Su Hwa ^b   So, Insuk ^b,c   Jeon, Ju Hong ^b,c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Bioinformatics; Gene expression profiling; Icilin; Microarray; Prostate cancer

Indexed keywords

1 (2 HYDROXYPHENYL) 4 (3 NITROPHENYL) 1,2,3,6 TETRAHYDROPYRIMIDIN 2 ONE; AHCTF1 PROTEIN; ANTINEOPLASTIC AGENT; CRABP2 PROTEIN; DNA METHYLTRANSFERASE 1; EWSR1 PROTEIN; HBP1 PROTEIN; HISTONE DEACETYLASE 2; JMJD1C PROTEIN; MXD4 PROTEIN; MYBBP1A PROTEIN; PROTEIN; PROTEIN TIMELESS; TEAD4 PROTEIN; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR E2F2; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; YWHAH PROTEIN;

ARTICLE; CELL CYCLE REGULATION; CONTROLLED STUDY; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MALE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BIOINFORMATICS; GENE EXPRESSION PROFILING; ICILIN; MICROARRAY; PROSTATE CANCER;

CELL CYCLE; CELL LINE, TUMOR; DNA, SUPERHELICAL; E2F1 TRANSCRIPTION FACTOR; HUMANS; MALE; PROSTATIC NEOPLASMS; PYRIMIDINONES;

EID: 84888850501     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.11.015     Document Type: Article

References (28)

1. Steinkamp M.P., O'Mahony O.A., Brogley M., Rehman H., Lapensee E.W., Dhanasekaran S., Hofer M.D., Kuefer R., Chinnaiyan A., Rubin M.A., Pienta K.J., Robins D.M. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res. 2009, 69:4434-4442.
2. Ahmed M., Li L.C. Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective. Int. J. Urol. 2013, 20:362-371.
3. Balk S.P., Knudsen K.E. AR, the cell cycle, and prostate cancer. Nucl. Recept. Signal. 2008, 6:e001.
4. Chandran U.R., Ma C., Dhir R., Bisceglia M., Lyons-Weiler M., Liang W., Michalopoulos G., Becich M., Monzon F.A. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 2007, 7:64.
5. Lee J.T., Lehmann B.D., Terrian D.M., Chappell W.H., Stivala F., Libra M., Martelli A.M., Steelman L.S., McCubrey J.A. Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell cycle 2008, 7:1745-1762.
6. Kim S.H., Kim S.Y., Park E.J., Kim J., Park H.H., So I., Kim S.J., Jeon J.H. Icilin induces G1 arrest through activating JNK and p38 kinase in a TRPM8-independent manner. Biochem. Biophys. Res. Commun. 2011, 406:30-35.
7. Kim S.-H., Lee S., Piccolo S.R., Allen-Brady K., Park E.-J., Chun J.N., Kim T.W., Cho N.-H., Kim I.-G., So I. Menthol induces cell-cycle arrest in PC-3 cells by down-regulating G2/M genes, including polo-like kinase 1. Biochem. Biophys. Res. Commun. 2012, 422:436-441.
8. Hubble J., Demeter J., Jin H., Mao M., Nitzberg M., Reddy T., Wymore F., Zachariah Z.K., Sherlock G., Ball C.A. Implementation of genepattern within the stanford microarray database. Nucleic Acids Res. 2009, 37:D898-D901.
9. Tusher V.G., Tibshirani R., Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. 2001, 98:5116-5121.
10. Basso K., Margolin A.A., Stolovitzky G., Klein U., Dalla-Favera R., Califano A. Reverse engineering of regulatory networks in human B cells. Nat. Genet. 2005, 37:382-390.
11. Margolin A.A., Nemenman I., Basso K., Wiggins C., Stolovitzky G., Favera R.D., Califano A. ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context. BMC Bioinformatics 2006, 7:S7.
12. Lefebvre C., Rajbhandari P., Alvarez M.J., Bandaru P., Lim W.K., Sato M., Wang K., Sumazin P., Kustagi M., Bisikirska B.C. A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centers. Mol. Syst. Biol. 2010, 6.
13. Lim W.K., Lyashenko E., Califano A. Master regulators used as breast cancer metastasis classifier 2009, NIH Public Access, Pacific Symposium on Biocomputing, p. 504.
14. Kim K., Oh M., Ki H., Wang T., Bareiss S., Fini M.E., Li D., Lu Q. Identification of E2F1 as a positive transcriptional regulator for delta-catenin. Biochem. Biophys. Res. Commun. 2008, 369:414-420.
15. Dong Q., Meng P., Wang T., Qin W., Qin W., Wang F., Yuan J., Chen Z., Yang A., Wang H. MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS One 2010, 5:e10147.
16. Jeon J.H., Choi K.H., Cho S.Y., Kim C.W., Shin D.M., Kwon J.C., Song K.Y., Park S.C., Kim I.G. Transglutaminase 2 inhibits Rb binding of human papillomavirus E7 by incorporating polyamine. EMBO J. 2003, 22:5273-5282.
17. Lee C.R., Chun J.N., Kim S.Y., Park S., Kim S.H., Park E.J., Kim I.S., Cho N.H., Kim I.G., So I., Kim T.W., Jeon J.H. Cyclosporin A suppresses prostate cancer cell growth through CaMKKbeta/AMPK-mediated inhibition of mTORC1 signaling. Biochem. Pharmacol. 2012, 84:425-431.
18. Park E.J., Kim S.Y., Kim S.H., Lee C.R., Kim I.S., Park J.K., Lee S.W., Kim B.J., Chun J.N., So I., Jeon J.H. SK&F 96365 induces apoptosis and autophagy by inhibiting Akt-mTOR signaling in A7r5 cells. Biochim. Biophys. Acta 1813, 2011:2157-2164.
19. R.C. Team, R: a language and environment for statistical computing, ISBN 3-900051-07-0. R Foundation for Statistical Computing, Vienna, Austria, 2013. URL: 2005. http://www.R-project.org.
20. Chen H.-Z., Tsai S.-Y., Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat. Rev. Cancer 2009, 9:785-797.
21. Engelmann D., Putzer B.M. The dark side of E2F1: in transit beyond apoptosis. Cancer Res. 2012, 72:571-575.
22. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 1998, 12:2245-2262.
23. Bracken A.P., Pasini D., Capra M., Prosperini E., Colli E., Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 2003, 22:5323-5335.
24. Kaseb A.O., Chinnakannu K., Chen D., Sivanandam A., Tejwani S., Menon M., Dou Q.P., Reddy G.P. Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. Cancer Res. 2007, 67:7782-7788.
25. Altintas D.M., Shukla M.S., Goutte-Gattat D., Angelov D., Rouault J.P., Dimitrov S., Samarut J. Direct cooperation between androgen receptor and E2F1 reveals a common regulation mechanism for androgen-responsive genes in prostate cells. Mol. Endocrinol. 2012, 26:1531-1541.
26. Hahm E.R., Singh S.V. Honokiol causes G0-G1 phase cell cycle arrest in human prostate cancer cells in association with suppression of retinoblastoma protein level/phosphorylation and inhibition of E2F1 transcriptional activity. Mol. Cancer Ther. 2007, 6:2686-2695.
27. Fujita Y., Kojima K., Hamada N., Ohhashi R., Akao Y., Nozawa Y., Deguchi T., Ito M. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem. Biophys. Res. Commun. 2008, 377:114-119.
28. Freyhult E., Landfors M., Onskog J., Hvidsten T.R., Ryden P. Challenges in microarray class discovery: a comprehensive examination of normalization, gene selection and clustering. BMC Bioinformatics 2010, 11:503.